全文获取类型
收费全文 | 296107篇 |
免费 | 17168篇 |
国内免费 | 414篇 |
专业分类
耳鼻咽喉 | 4205篇 |
儿科学 | 10283篇 |
妇产科学 | 10243篇 |
基础医学 | 44943篇 |
口腔科学 | 7496篇 |
临床医学 | 24146篇 |
内科学 | 55747篇 |
皮肤病学 | 6309篇 |
神经病学 | 20992篇 |
特种医学 | 11610篇 |
外国民族医学 | 43篇 |
外科学 | 46650篇 |
综合类 | 7765篇 |
现状与发展 | 1篇 |
一般理论 | 160篇 |
预防医学 | 19893篇 |
眼科学 | 6943篇 |
药学 | 20865篇 |
中国医学 | 787篇 |
肿瘤学 | 14608篇 |
出版年
2018年 | 3611篇 |
2017年 | 2650篇 |
2016年 | 3069篇 |
2015年 | 3486篇 |
2014年 | 4569篇 |
2013年 | 7198篇 |
2012年 | 9050篇 |
2011年 | 9435篇 |
2010年 | 6119篇 |
2009年 | 5541篇 |
2008年 | 8659篇 |
2007年 | 9507篇 |
2006年 | 9348篇 |
2005年 | 8944篇 |
2004年 | 8654篇 |
2003年 | 8157篇 |
2002年 | 7753篇 |
2001年 | 13318篇 |
2000年 | 13646篇 |
1999年 | 11415篇 |
1998年 | 3022篇 |
1997年 | 2788篇 |
1996年 | 2633篇 |
1995年 | 2544篇 |
1994年 | 2342篇 |
1992年 | 8312篇 |
1991年 | 8449篇 |
1990年 | 8259篇 |
1989年 | 8075篇 |
1988年 | 7313篇 |
1987年 | 7071篇 |
1986年 | 6719篇 |
1985年 | 6514篇 |
1984年 | 4760篇 |
1983年 | 4118篇 |
1982年 | 2469篇 |
1979年 | 4427篇 |
1978年 | 3228篇 |
1977年 | 2731篇 |
1976年 | 2503篇 |
1975年 | 2833篇 |
1974年 | 3352篇 |
1973年 | 3362篇 |
1972年 | 3118篇 |
1971年 | 2948篇 |
1970年 | 2838篇 |
1969年 | 2581篇 |
1968年 | 2538篇 |
1967年 | 2373篇 |
1966年 | 2264篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
11.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
12.
13.
14.
15.
16.
Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers 下载免费PDF全文
17.
18.
19.
Gastro-oesophageal reflux disease (GORD) is symptomatic reflux of gastric contents into the oesophagus. Factors predisposing to GORD are loss of the physiological antireflux barrier and anatomic abnormalities of the oesophagus or diaphragm. Conservative measures and medical management results in resolution of symptoms in a majority of children. Surgery is indicated in the event of failure of medical management or severe complications. Surgical procedures include open or laparoscopic fundoplication in children with normal neurology; fundoplication with or without vagotomy and pyloroplasty; surgical feeding jejunostomy and oesophago-gastric dissociation in the severely neurologically impaired children. 相似文献
20.
O. Morris M. Fairclough J. Grigg C. Prenant A. McMahon 《Journal of labelled compounds & radiopharmaceuticals》2019,62(1):4-23
Affinity peptide and protein‐ (APP) based radiotracers are an increasingly popular class of radiotracer in positron emission tomography (PET), which was once dominated by the use of small molecule radiotracers. Radiolabelled monoclonal antibodies (mAbs) are important examples of APPs, yet a preference for smaller APPs, which exhibit fast pharmacokinetics and permit rapid PET aided diagnosis, has become apparent. 18F exhibits favourable physical characteristics for APP radiolabelling and has been described as an ideal PET radionuclide. Notwithstanding, 18F radiolabelling of APP is challenging, and this is echoed in the literature where a number of diverse approaches have been adopted. This review seeks to assess and compare the approaches taken to 18F APP radiolabelling with the intention of highlighting trends within this expanding field. Generic themes have emerged in the literature, namely the use of mild radiolabelling conditions, a preference of site‐specific methodologies with an impetus for short, automated procedures which produce high‐yielding [18F]APPs. 相似文献